ArticleThoracic cancer2024

Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.

Yun Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.